Tetraphase Pharmaceuticals (TTPH) Rating Reiterated by SunTrust Banks

Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “buy” rating restated by SunTrust Banks in a report issued on Wednesday. They presently have a $10.00 target price on the biopharmaceutical company’s stock. SunTrust Banks’ target price would suggest a potential upside of 84.16% from the stock’s previous close.

Several other equities research analysts have also issued reports on TTPH. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. HC Wainwright increased their price objective on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, B. Riley initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $11.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Tetraphase Pharmaceuticals has a consensus rating of “Hold” and an average target price of $10.39.

Tetraphase Pharmaceuticals (TTPH) traded down $0.03 during trading on Wednesday, hitting $5.43. 1,225,600 shares of the stock traded hands, compared to its average volume of 969,319. Tetraphase Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $9.93. The firm has a market capitalization of $281.71, a price-to-earnings ratio of -1.90 and a beta of 2.29.

In other news, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director L Patrick Gage bought 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was purchased at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the purchase, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at $107,000. Brighton Jones LLC bought a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at $108,000. Voya Investment Management LLC boosted its stake in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at $147,000. Finally, Ameriprise Financial Inc. bought a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at $162,000. Hedge funds and other institutional investors own 58.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/tetraphase-pharmaceuticals-ttph-rating-reiterated-by-suntrust-banks.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply